Cognitive & Neuro Regulation

Noopept (N-Phenylacetyl-L-Prolylglycine Ethyl Ester)

For Research Use Only. Not for Human or Veterinary Use.

Overview

Noopept is a synthetic nootropic compound — the ethyl ester of N-phenylacetyl-L-prolylglycine — designed as a small-molecule mimetic of the endogenous cyclic dipeptide cyclo-L-prolylglycine. Although it sits in this peptide database and has a proline-glycine backbone, it is really a peptide-derived small molecule, not a standard peptide. In research it is studied for cognitive enhancement and neuroprotection via AMPA-receptor modulation and BDNF induction. It is a research compound.

Chemical Profile

PropertyValue
CAS number157115-85-0
ClassDipeptide-derived nootropic (small molecule)
Chemical nameN-phenylacetyl-L-prolylglycine ethyl ester
Molecular formulaC₁₇H₂₂N₂O₄
Molecular weight342.39 g/mol
Purity (HPLC)≥ 99%
AppearanceWhite crystalline powder
Noopept at a glance
Class
Dipeptide-derived nootropic small molecule
Design basis
Mimetic of cyclo-L-prolylglycine
Research status
Preclinical and clinical (Russia)
Study routes
Oral, sublingual
Half-life
≈ 2–5 h (oral)
Key feature
AMPA-receptor facilitation; BDNF induction

Mechanism of Action

Noopept was designed as a mimetic of cyclo-L-prolylglycine, a metabolite linked to the older nootropic piracetam. Its studied action is multimodal: positive modulation of AMPA-type glutamate receptors (supporting synaptic transmission) together with induction of BDNF/NGF and the neuroplasticity signalling that follows.

ComponentDetail
Primary targetAMPA-type glutamate receptors (positive modulation)
NeurotrophicUpregulation of BDNF and NGF expression
MetaboliteStudied as a mimetic of cyclo-L-prolylglycine
AntioxidantReported antioxidant / anti-apoptotic effects
CholinergicModulation of cholinergic transmission

Pharmacology

ParameterValue
Half-life (t½)≈ 2–5 h (oral)
BioavailabilityOral / sublingual activity
MetabolismHydrolysis to active metabolites (incl. cycloprolylglycine)
Route of administrationOral, sublingual
EliminationRenal (metabolites)

Research Evidence

Representative studies and their focus are named below; specific numerical outcomes are not restated here as claims.

Study typeResearch focusReference
Rodent cognition modelsMemory consolidation and learningNoopept preclinical literature
Neuroprotection modelsOxidative stress and neuronal survivalNoopept preclinical literature
Clinical cognition observationMild cognitive impairment researchNoopept clinical literature (Russia)

Representative reported directions from the literature (qualitative; GLP-1 entries reflect published clinical-trial results, others are reported study directions, not restated as precise product claims):

Reported direction / findingContextReference
Improved memory consolidation and learningrodent cognitionNoopept literature
Neuroprotection via AMPA modulation and BDNF inductionneuronal modelsNoopept literature

For laboratory research use only. Not for human or veterinary use, diagnosis, or therapeutic application. Descriptions refer to published research contexts and are not medical or product claims.

Dosing & Handling Reference

Handling parameters for laboratory research. Not dosing guidance for human use.

ParameterReference value
Research dose range (literature)≈ 10–20 mg per dose, in study protocols
Solvent (for solutions)Water / saline (readily soluble)
Storage2–8°C, protected from light
Do not useIf material shows discoloration or degradation

Safety Profile

Published research observations, provided for reference only. This material is not for human or veterinary use.

CategoryPublished observations
TolerabilityWell tolerated in reported studies
Sedation / stimulationGenerally neither markedly sedating nor stimulating
CytotoxicityNo cytotoxicity reported at studied levels
StatusFor research use only; not for human or veterinary application

Physicochemical Properties

PropertyValue
Physical stateWhite crystalline powder
Solubility (water)Soluble
Chemical typeSmall molecule (peptide-derived)
StabilityStable refrigerated, protected from light

Synthesis & Manufacturing

Noopept is made by solution-phase organic synthesis — phenylacetylation of proline, coupling to glycine, and esterification — rather than by solid-phase peptide synthesis, and is characterised by NMR and MS as a small molecule.

  • Solution-phase organic synthesis (phenylacetyl-proline → prolylglycine ethyl ester)
  • Crystallization / chromatographic purification to ≥ 99%
  • Identity confirmed by NMR and mass spectrometry

Analytical Methods

Noopept is a peptide-derived small molecule, so it is characterised by the organic-chemistry panel (NMR, MS, HPLC) rather than by peptide-specific assays. A key attribute is confirming the intact ethyl ester (its main hydrolysis point).

MethodPurposeTypical result
RP-HPLC (C18, UV 210 nm)Purity≥ 99%
¹H / ¹³C NMRStructure confirmationConsistent with the phenylacetyl-prolylglycine ethyl ester
ESI-MS / HRMSIdentity / accurate mass[M+H]⁺ ≈ 343 Da
IR spectroscopyEster / amide confirmationCharacteristic carbonyl bands
Melting pointIdentitySharp, characteristic
Chiral HPLCConfirm L-proline configurationSingle enantiomer
Karl FischerWater contentLow (per specification)
Residual solvents (GC)ICH Q3C limitsWithin limits

Representative HPLC method:

  • Column: C18, 5 µm, 250 × 4.6 mm
  • Mobile phase: aqueous buffer / acetonitrile gradient · Flow rate: 1.0 mL/min
  • Detection: UV 210 nm · Identity confirmed by NMR + HRMS; chirality by chiral HPLC

Stability Data

ConditionDurationResult
Solid, 2–8°C, dry, dark≥ 36 monthsStable
Solid, room temperature, dry≥ 24 monthsStable
Solid, 40°C (accelerated)3 monthsNo significant degradation
Aqueous solution, 2–8°C≈ 2 weeksSlow ester hydrolysis
Aqueous solution, 25°CDaysFaster ester hydrolysis — prepare fresh
Photostability (ICH Q1B)StandardLow light sensitivity
  • As a solid it is very stable when kept dry and cold.
  • In solution the ethyl ester slowly hydrolyses (to the acid / cycloprolylglycine metabolite), so prepare working solutions fresh and keep them cold.

Selected References

  • Noopept (GVS-111) nootropic and neuroprotection research literature.
  • Reviews of proline-containing dipeptide nootropics and cycloprolylglycine.

Quality & Supply

  • HPLC ≥ 99% purity with a Certificate of Analysis per batch
  • Identity confirmed by NMR and mass spectrometry
  • Research quantities through to bulk, with worldwide delivery
  • Custom quantities and packaging on request

Need Noopept — sample or bulk?

HPLC-verified, COA per batch. Tell us the quantity you need.

Request a Quote